Enhanced Blood-Brain Barrier Penetrability of BACE1 SiRNA-Loaded Prussian Blue Nanocomplexes for Alzheimer's Disease Synergy Therapy

Abstract

Amyloid-β (Aβ) deposition was an important pathomechanisms of Alzheimer's disease (AD). Aβ generation was highly regulated by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is a prime drug target for AD therapy. The silence of BACE1 function to slow down Aβ production was accepted as an effective strategy for combating AD. Herein, BACE1 interfering RNA, metallothionein (MT) and ruthenium complexes ([Ru(bpy)₂dppz]²⁺) were all loaded in Prussian blue nanoparticles (PRM-siRNA). PRM-siRNA under near-infrared light irradiation showed good photothermal effect and triggered instantaneous opening of blood-brain barrier (BBB) for enhanced drug delivery. BACE1 siRNA slowed down Aβ production and Cu²⁺ chelation by metallothionein (MT) synergistically inhibited Aβ aggregation. Ruthenium (Ru) could real-timely track Aβ degradation and aggregation. The results indicated that PRM-siRNA significantly blocked Aβ aggregation and attenuated Aβ-induced neurotoxicity and apoptosis in vitro by inhibiting ROS-mediated oxidative damage and mitochondrial dysfunction through regulating the Bcl-2 family. PRM-siRNA in vivo effectively improved APP/PS1 mice learning and memory by alleviating neural loss, neurofibrillary tangles and activation of astrocytes and microglial cells in APP/PS1 mice by inhibiting BACE1, oxidative damage and tau phosphorylation. Taken together, our findings validated that BACE1 siRNA-loaded Prussian blue nanocomplexes showed enhanced BBB penetrability and AD synergy therapy.

Keywords

Alzheimer's disease / amyloid-β / BACE1 / blood-brain barrier / Prussian blue nanoparticles

References

[1] F. E. Ali, F. Separovic, C. J. Barrow, S. Yao, and K. J. Barnham, “Copper and Zinc Mediated Oligomerisation of Aβ Peptides,” International Journal of Peptide Research and Therapeutics 12 (2006): 153-164.

[2] G. R. Behbehani, “A Novel Method for Thermodynamic Study on Binding of Copper Ion With Alzheimer's Amyliod β Peptide,” Chinese Science Bulletin 54 (2009): 1037-1042.

[3] G. R. Behbehani, L. Barzegar, M. Mohebbian, and A. A. Saboury, “A Comparative Interaction Between Copper Ions With Alzheimer′s β Amyloid Peptide and Human Serum Albumin,” Bioinorganic Chemistry and Applications 2012 (2012): 208641.

[4] V. C. Epa, V. A. Streltsov, and J. N. Varghese, “Modelling Copper Binding to the Amyloid-β Peptide in Alzheimer,” Australian Journal of Chemistry 63 (2010): 345-349.

[5] N. K. Isaev, E. V. Stelmashook, and E. E. Genrikhs, “Role of Zinc and Copper Ions in the Pathogenetic Mechanisms of Traumatic Brain Injury and Alzheimer's Disease,” Reviews Neuroscience 31 (2020): 233-243.

[6] J. W. Karr, L. J. Kaupp, and V. A. Szalai, “Amyloid-β Binds Cu²⁺ in a Mononuclear Metal Ion Binding Site,” Journal of the American Chemical Society 126 (2004): 13534-13538.

[7] M. Li, Y. Guan, C. Ding, Z. Chen, J. Ren, and X. Qu, “An Ultrathin Graphitic Carbon Nitride Nanosheet: A Novel Inhibitor of Metal-Induced Amyloid Aggregation Associated With Alzheimer's Disease,” Journal of Materials Chemistry B 4 (2016): 4072-4075.

[8] C. J. Matheou, N. D. Younan, and J. H. Viles, “Cu²⁺ accentuates Distinct Misfolding of Aβ(1-40) and Aβ(1-42) Peptides, and Potentiates Membrane Disruption,” Biochemical Journal 466 (2015): 233-242.

[9] Y.-B. Peng, C. Tao, C.-P. Tan, and P. Zhao, “Inhibition of Aβ Peptide Aggregation by Ruthenium(II) Polypyridyl Complexes Through Copper Chelation,” Journal of Inorganic Biochemistry 224 (2021): 111591.

[10] C. D. Syme, R. C. Nadal, S. E. J. Rigby, and J. H. Viles, “Copper Binding to the Amyloid-β (Aβ) Peptide Associated With Alzheimer's Disease,” Journal of Biological Chemistry 279 (2004): 18169-18177.

[11] V. Tougu, A. Karafin, and P. Palumaa, “Binding of Zinc(II) and Copper(II) to the Full-Length Alzheimer's Amyloid-β Peptide,” Journal of Neurochemistry 104 (2008): 1249-1259.

[12] N. P. Shah, V. S. Solanki, and A. S. Gurjar, “Advancements in BACE1 and Non-Peptide BACE1 Inhibitors for Alzheimer's Disease,” Indian Journal of Chemistry 57 (2018): 830-842.

[13] R. Yan and R. Vassar, “Targeting the β Secretase BACE1 for Alzheimer's Disease Therapy,” Lancet Neurology 13 (2014): 319-329.

[14] S. L. Cole and R. Vassar, “The Alzheimer's Disease Beta-secretase Enzyme, BACE1,” Molecular Neurodegeneration 2 (2007): 22.

[15] D. W. Klaver, M. C. J. Wilce, H. Cui, et al., “Is BACE1 a Suitable Therapeutic Target for the Treatment of Alzheimer's disease? Current Strategies and Future Directions,” Biological Chemistry 391, no. 8 (2010): 849-859.

[16] C. Zhang, Z. Gu, L. Shen, X. Liu, and H. Lin, “In Vivo Evaluation and Alzheimer's Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System,” Current Pharmaceutical Biotechnology 20, no.1 (2019): 56-62.

[17] Y. Zhou, F. Zhu, Y. Liu, et al., “Blood-Brain Barrier-penetrating siRNA Nanomedicine for Alzheimer's Disease Therapy,” Science Advances 6, no. 41 (2020): eabc7031.

[18] G. Rassu, E. Soddu, A. M. Posadino, et al., “Nose-to-Brain Delivery of BACE1 siRNA Loaded in Solid Lipid Nanoparticles for Alzheimer's Therapy,” Colloids and Surfaces B: Biointerfaces 152 (2017): 296-301.

[19] P. Wang, X. Zheng, Q. Guo, et al., “Systemic Delivery of BACE1 siRNA Through Neuron-targeted Nanocomplexes for Treatment of Alzheimer's Disease,” Journal of Controlled Release 279 (2018): 220-233.

[20] C. Zhang, Z. C. Gu, L. Shen, X. Y. Liu, and H. W. Lin, “A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering siRNA to Neurons for Alzheimer's Disease Treatment,” Current Pharmaceutical Biotechnology 18 (2017): 1124-1131.

[21] X. Zheng, X. Pang, P. Yang, et al., “A Hybrid siRNA Delivery Complex for Enhanced Brain Penetration and Precise Amyloid Plaque Targeting in Alzheimer's disease Mice,” Acta Biomaterialia 49 (2017): 388-401.

[22] R. Acharya, S. Saha, S. Ray, S. Hazra, M. K. Mitra, and J. Chakraborty, “siRNA-Nanoparticle Conjugate in Gene Silencing: A Future Cure to Deadly Diseases?,” Materials Science & Engineering: C 76 (2017): 1378-1400.

[23] Q. Guo, X. Zheng, P. Yang, et al., “Small Interfering RNA Delivery to the Neurons near the Amyloid Plaques for Improved Treatment of Alzheimer׳s Disease,” Acta Pharmaceutica Sinica B 9 (2019): 590-603.

[24] N. Lopez-Barbosa, J. G. Garcia, J. Cifuentes, et al., “Multifunctional Magnetite Nanoparticles to Enable Delivery of siRNA for the Potential Treatment of Alzheimer's,” Drug Delivery 27, no.1 (2020): 864-875.

[25] M. A. Busquets and J. Estelrich, “Prussian Blue Nanoparticles: Synthesis, Surface Modification, and Biomedical Applications,” Drug Discovery Today 25 (2020): 1431-1443.

[26] M. Cahu, L. M. A. Ali, S. Sene, et al., “A Rational Study of the Influence of Mn²⁺-Insertion in Prussian Blue Nanoparticles on Their Photothermal Properties,” Journal of Materials Chemistry B 9 (2021): 9670-9683.

[27] H. Gao, B. Chi, F. Tian, et al., “Prussian Blue modified Metal Organic Frameworks for imaging guided synergetic tumor therapy with hypoxia modulation,” Journal of Alloys and Compounds 853 (2021): 157329.

[28] Y. Ma, H. Chen, B. Hao, et al., “A Chloroquine-Loaded Prussian Blue Platform With Controllable Autophagy Inhibition for Enhanced Photothermal Therapy,” Journal of Materials Chemistry B 6 (2018): 5854-5859.

[29] A. H. Odda, H. Li, N. Kumar, et al., “Polydopamine Coated PB-MnO₂ Nanoparticles as an Oxygen Generator Nanosystem for Imaging-Guided Single-NIR-Laser Triggered Synergistic Photodynamic/Photothermal Therapy,” Bioconjugate Chemistry 31 (2020): 1474-1484.

[30] M. Wu, Q. Wang, X. Liu, and J. Liu, “Highly Efficient Loading of Doxorubicin in Prussian Blue Nanocages for Combined Photothermal/Chemotherapy Against Hepatocellular Carcinoma,” RSC Advances 5 (2015): 30970-30980.

[31] F. Gosselet, P. Candela, R. Cecchelli, and L. Fenart, “Role of the Blood-Brain Barrier in Alzheimer's Disease,” Medical Sciences 27, no.11 (2011): 987-992.

[32] Y. Shin, S. H. Choi, E. Kim, et al., “Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease,” Advanced Science 6, no. 20 (2019): 1900962.

[33] Y. L. Wang, J. Liu, Z. M. Zhang, X. L. Wang, and C. D. Zhang, “Structure and Permeability Changes of the Blood-Brain Barrier in APP/PS1 Mice: An Alzheimer's Disease Animal Model,” Journal of Neurochemistry 5 (2011): 220.

[34] M. Zhao, X.-F. Jiang, H.-Q. Zhang, et al., “Interactions Between Glial Cells and the Blood-Brain Barrier and Their Role in Alzheimer's Disease,” Ageing Research Reviews 72 (2021): 101483.

[35] W. S. Chen, J. Ouyang, X. Y. Yi, et al., “Black Phosphorus Nanosheets as a Neuroprotective Nanomedicine for Neurodegenerative Disorder Therapy,” Advanced Materials 30, no. 3 (2018): 1703458.

[36] Z. Qin, Y. Li, and N. Gu, “Progress in Applications of Prussian Blue Nanoparticles in Biomedicine,” Advanced Healthcare Materials 7 (2018): 1800347.

[37] Y. Heo, K. Kim, J. Kim, J. Jang, and C. B. Park, “Near-Infrared-Active Copper Bismuth Oxide Electrodes for Targeted Dissociation of Alzheimer's β-Amyloid Aggregates,” ACS Applied Materials & Interfaces 12 (2020): 23667.

[38] K. Deng, C. Li, S. Huang, et al., “Recent Progress in Near Infrared Light Triggered Photodynamic Therapy,” Small 13 (2017): 1702299.

[39] X. Song, Q. Ding, W. Wei, et al., “Peptide-Functionalized Prussian Blue Nanomaterial for Antioxidant Stress and NIR Photothermal Therapy Against Alzheimer's Disease,” Small 19 (2023): 2206959.

[40] C. O. Simpkins, “Metallothionein in Human Disease,” Cell and Molecular Biology 46 (2000): 465-488.

[41] W. H. Yu, W. J. Lukiw, C. Bergeron, H. B. Niznik, and P. E. Fraser, “Metallothionein III is Reduced in Alzheimer's Disease,” Brain Research 894 (2001): 37-45.

[42] A. Avan and T. U. Hoogenraad, “Zinc and Copper in Alzheimer's Disease,” Journal of Alzheimer's Disease 46 (2015): 89-92.

[43] X. Lv and X. Tan, “Metals Homeostasis and Related Proteins in Alzheimer's Disease,” Progress in Chemistry 25 (2013): 511-519.

[44] N. P. Cook, V. Torres, D. Jain, and A. A. Marti, “Sensing Amyloid-β Aggregation Using Luminescent Dipyridophenazine Ruthenium(II) Complexes,” Journal of the American Chemical Society 133 (2011): 11121-11123.

[45] R. Mito, D. Raffelt, T. Dhollander, et al., “Fibre-Specific White Matter Reductions in Alzheimer's Disease and Mild Cognitive Impairment,” Brain 141 (2018): 888-902.

[46] S. Kar and R. Quirion, “Amyloid β Peptides and Central Cholinergic Neurons: Functional Interrelationship and Relevance to Alzheimer's Disease Pathology,” Progress in Brain Research 145 (2004): 261-274.

[47] H. Sato, M. Ide, R. Saito, et al., “Electrochemical Interfacing of Prussian Blue Nanocrystals With an ITO Electrode Modified With a Thin Film Containing a Ru Complex,” Journal of Materials Chemistry C 7 (2019): 12491-12501.

[48] C. Fan, W. Zheng, X. Fu, X. Li, Y.-S. Wong, and T. Chen, “Strategy to Enhance the Therapeutic Effect of Doxorubicin in human Hepatocellular Carcinoma by Selenocystine, a Synergistic Agent That Regulates the ROS-mediated Signaling,” Oncotarget 5 (2014): 2853-2863.

[49] Y. Huang, L. He, W. Liu, et al., “Selective Cellular Uptake and Induction of Apoptosis of Cancer-Targeted Selenium Nanoparticles,” Biomaterials 34 (2013): 7106-7116.

[50] C. Fan, W. Zheng, X. Fu, X. Li, Y. Wong, and T. Chen, “Enhancement of Auranofin-Induced Lung Cancer Cell Apoptosis by Selenocystine, a Natural Inhibitor of TrxR1 In Vitro and In Vivo,” Cell Death & Disease 5 (2014): e1191.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.